Glucagon-like peptide 1 (GLP-1) analogues represent a new class of anti-diabetes medications that, through their glucose-dependent mechanism of action, may avoid some of the limitations of earlier-generation agents. The gene discussed is GLP1R; the disease is diabetes mellitus.